{"entity":{"id":"nct07223047","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance","aka":[],"tldr":"A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.","summary":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT07223047 by Bristol-Myers Squibb, with 252 participants planned, started 2025-11-25 and due to reach its primary completion in 2028-10-13. Interventions recorded: BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab. Conditions listed: Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07223047","url":"https://clinicaltrials.gov/study/NCT07223047"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine","paclitaxel","cetuximab","pembrolizumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07223047","phase":"1/2","setting":"A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT07223047","source":"https://clinicaltrials.gov/study/NCT07223047","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"064e59ec8ce213c15afcbc75e6df66c45d3a2490fd359b7c2cecb89184d3c3e0","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-28","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":252,"enrolmentType":"ESTIMATED","siteCount":8,"recruitingSiteCount":6,"countries":["Canada","Spain","United States"]}],"started":"2025-11-25","startedType":"actual","enrolled":252,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07223047/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}